Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Change in Account Payables (2020 - 2025)

Rani Therapeutics Holdings has reported Change in Account Payables over the past 6 years, most recently at -$2.2 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$2.2 million for Q4 2025, down 942.51% from a year ago — trailing twelve months through Dec 2025 was -$1.0 million (down 247.68% YoY), and the annual figure for FY2025 was -$1.0 million, down 247.68%.
  • Change in Account Payables for Q4 2025 was -$2.2 million at Rani Therapeutics Holdings, down from $669000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for RANI hit a ceiling of $1.1 million in Q3 2024 and a floor of -$2.2 million in Q4 2025.
  • Median Change in Account Payables over the past 5 years was $104500.0 (2022), compared with a mean of -$39500.0.
  • Biggest five-year swings in Change in Account Payables: surged 362.5% in 2022 and later crashed 942.51% in 2025.
  • Rani Therapeutics Holdings' Change in Account Payables stood at -$693000.0 in 2021, then skyrocketed by 69.12% to -$214000.0 in 2022, then crashed by 209.81% to -$663000.0 in 2023, then surged by 68.78% to -$207000.0 in 2024, then crashed by 942.51% to -$2.2 million in 2025.
  • The last three reported values for Change in Account Payables were -$2.2 million (Q4 2025), $669000.0 (Q3 2025), and $278000.0 (Q2 2025) per Business Quant data.